As chief science policy officer for Global Healthy Living Foundation, Robert Popovian, PharmD, MS, has a bird’s-eye view of some of the central issues of biosimilar access in the United States.
The Global Healthy Living Foundation is a volunteer organization that works to improve the lives of individuals with chronic conditions. Given that, the group has a natural interest in seeing improvements in patience access to critical medicines, such as biosimilars, which are equivalent to reference biologics and can help bring down the costs of treatment.
In this interview, Tony Hagen, senior editor for The Center for Biosimilars®, talks with Robert Popovian, PharmD, MS, who serves as chief science policy officer at GHLF, about a recent podcast series the group did to promote wider understanding of biosimilars. Popovian provides his impressions of progress toward biosimilar availability in the United States and the value of biosimilar education for patients and providers.
Popovian is also vice president of Health Economics and Policy for ConsenSys Health and a senior health policy fellow at the Progressive Policy Institute. To access the podcasts on biosimilars produced by GHLF, use this link.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.